Anna D. Garrett, PharmD, BCPS, CPP
Published Online: Wednesday, November 1, 2006

The FDA recently announced an update to the product labeling for the Ortho-Evra contraceptive patch. Information regarding the risk of developing venous thromboembolism has been changed, based on increased concerns that the patch increases the risk of blood clots, compared with other types of birth control with similar ingredients. Two recent studies produced conflicting data regarding this issue, but the agency determined that the concerns were great enough to support the labeling change.

The majority of women can use the patch safely. The risk of embolic events, however, increases significantly with smoking, high blood pressure, diabetes, high cholesterol, a family history of clotting disorders, heart attack, stroke, chest pain, certain types of cancer, jaundice, or liver tumors. Women should consider an alternative method of birth control if any of these conditions exist.

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

Latest Articles
Janssen Research and Development LLC has submitted a new drug application to the FDA for canagliflozin and metformin hydrochloride extended release (Invokamet XR).
Treating chronic pulmonary obstructive disease with both inhaled corticosteroids and long-acting bronchodilators remains controversial, but new evidence suggests that this controller combination could reduce mortality risk.
Beverly Schaefer, RPh, of Katterman's Sand Point Pharmacy in Seattle, Washington, shares some fun tips on how to encourage patients who travel to come to your pharmacy for supplies.
Donnie Calhoun, RPh, PD, National Community Pharmacists Association (NCPA) Foundation vice president, discusses how pharmacists can prepare themselves and their business before, during, and after a disaster.
Latest Issues